Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Multicenter, Open-label, Randomized, Parallel Groups Clinical Study to Compare Efficacy and Safety of Indinol Forto® 200 mg Capsules (LLC Alcea, Russia) and Visanne 2 mg Tablets (BAYER AG, Germany) in Treatment of Endometriosis

NCT07164183 is registered in ClinicalTrials.gov with Alcea as lead sponsor.

NCT NCT07164183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07164183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Multicenter, Open-label, Randomized, Parallel Groups Clinical Study to Compare Efficacy and Safety of Indinol Forto® 200 mg Capsules (LLC Alcea, Russia) and Visanne 2 mg Tablets (BAYER AG, Germany) in Treatment of Endometriosis
Lead sponsor
Alcea
Phase
Phase 3
Overall status
Recruiting
Start date
September 11, 2025
Completion date
November 30, 2026
Enrollment
290 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

endometriosis